4,901 trials
Infantile Colic · Infantile Functional Gastrointestinal Disorders
Primary: Drug Concentration Measurement in the Urine Collected by Diapers Along 24 Hours Post Dose and One Week After Dose in All Treated Infants and by Age and Dose Subgroups…
HIV Infections · Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) — 5.303; 8.964; 6.750; 6.515 micrograms (mcg)/mL
Pediatric Heterozygous Hypercholesterolemia
Primary: Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F) — 553; 543 L/hr
Heart Failure, Congestive
Primary: Number of Participants With Adverse Events by Severity From Week 0 Through Week 8 (CRV-IR) or Week 14 (SK&F-105517-D) — 0; 1; 2; 5 participants
Colorectal Neoplasms
Primary: Number of Participants With Adverse Events — 6; 6; 2; 4 participants
Healthy
Primary: Bioequivalence Based on Cmax — 1060.8; 1743.3 ng/mL
Healthy Subjects · Bioavailability · Pharmacokinetics
Primary: Bioequivalence Based on Cmax,ss — 1812.026; 3117.778 ng/mL
Healthy
Primary: Bioequivalence Based on AUC(0-t) — 33883; 32445; 32928; 31841 ng*h/mL
Healthy
Primary: Bioequivalence Based Cmax — 1230.7; 2947.7 ng/mL
Metastatic Breast Cancer
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 1; 1; 2; 1 Participants
Type 2 Diabetes Mellitus
Primary: Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose — 9.73; 8.03 ng/min — p=<0.001
Arthritis
Primary: Change in Balance — 0.2; 1.2; 1.0 units on a scale
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Guanfacine — 2.55; 2.97 ng/ml
Postmenopause
Primary: Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7 — 0.028; -0.011…
Healthy
Primary: Percent Change in Diameter of Radial Artery as a Dose Test for Nitroglycerin — -0.8; -0.2; 6.4; 2.5 percent diameter change